

Treatment Characteristics and Healthcare Resource Utilization Among Patients with Myasthenia Gravis Initiating Rozanolixizumab: A US Claims Database Analysis

Mohita Kumar¹, Alexandria Harrold², Minjee Park³, Aaksa Nair⁴, Kristina Bardenheuer⁵, Thaïs Tarancón⁶, Angela Ting^{1*}, Diogo Pata⁷

¹UCB, Atlanta, GA, USA; ²UCB, San Francisco, CA, USA; ³Alira Health, Basel, Switzerland;

⁴Alira Health, Framingham, MA, USA; ⁵UCB, Monheim, Germany; ⁶UCB, Madrid, Spain;

⁷UCB, Brussels, Belgium

*Affiliation at the time of the study


Corresponding author:

Mohita Kumar

UCB, Atlanta, GA, USA

Email: Mohita.Kumar@ucb.com

Supplementary Figure 1. Patient comorbidities during the baseline period among the cohort of patients who had ≥ 1 claim for efgartigimod (N=26)



*Psychological disorders included anxiety (n=7 [26.9%]) and depression (n=6 [23.1%]); patients could have both anxiety and depression. †Respiratory diseases included asthma (n=3 [11.5%]) and COPD (n=4 [15.4%]); patients could have both asthma and COPD. ‡Autoimmune diseases included type 1 diabetes (n=3 [11.5%]), autoimmune thyroiditis (n=2 [7.7%]), SLE (n=1 [3.8%]) and Crohn's disease (n=1 [3.8%]); patients could have >1 autoimmune disease. The baseline period comprised the 12 months prior to the index date. COPD, chronic obstructive pulmonary disease; SLE, systemic lupus erythematosus.